Price$4.64+0.22 (+4.98%)
01:30 PM07:45 PM
News · 26 weeks26-50%
2025-12-142026-06-07
Mix1490d
- SEC Filings5(36%)
- Other4(29%)
- Earnings2(14%)
- Offering2(14%)
- Insider1(7%)
Latest news
25 items- SECSEC Form SD filed by Apyx Medical CorporationSD - Apyx Medical Corp (0000719135) (Filer)
- PRBody by Apyx Takes Center Stage at Miami Swim Week Showcasing Real Patient Transformations and Confidence on the RunwayCLEARWATER, Fla., May 27, 2026 /PRNewswire/ -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical" or the "Company"), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), will return to Miami Swim Week with its Body by Apyx showcase, an immersive runway experience featuring real patient transformations. Building on last year's momentum, Apyx Medical has expanded its vision, introducing AYON, the next generation body contouring system designed to bring together the technologies surgeons rely on most into one comprehensiv
- SECApyx Medical Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Apyx Medical Corp (0000719135) (Filer)
- PRNew Study Shows Significant Improvement in Cellulite and Skin Laxity with Advanced Minimally Invasive Treatment Utilizing Avéli® and Renuvion®CLEARWATER, Fla., May 21, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the "Company" or "Apyx Medical"), the leader in surgical aesthetics products marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced the publication of new clinical data in Aesthetic Surgery Journal Open Forum highlighting a promising approach to improving cellulite and skin laxity, two of the most common aesthetic concerns among women. The prospective investigator initiated clinical study(1) evaluated a combination treatment approach utilizing Avéli® (Tiger Aesthetics Medical, LLC) for targeted subcision to disrupt fibrous septae, followed by Renuvion to reduce sk
- SECApyx Medical Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Apyx Medical Corp (0000719135) (Filer)
- PRApyx Medical Corporation Announces Retrospective Clinical Publication Evaluating Clinical Benefit of Renuvion® Used in Combination with LiposuctionCLEARWATER, Fla., May 14, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the "Company" or "Apyx Medical"), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced the publication of a new retrospective investigator-initiated study in Plastic and Reconstructive Surgery - Global Open1. The study evaluated patient-reported outcomes following liposuction with and without helium plasma radiofrequency (Renuvion). The results demonstrate that adding Renuvion to liposuction resulted in statistically significant improvements in patient-reported satisfaction with abdominal appearance and excess skin, along with
- SECApyx Medical Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Apyx Medical Corp (0000719135) (Filer)
- PRApyx Medical Corporation Receives Expanded FDA 510(k) Clearance Adding Power Liposuction Capability to AYON Body Contouring System™CLEARWATER Fla., May 11, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the "Company" or "Apyx Medical"), the leader in surgical aesthetics products marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced it received expanded 510(k) clearance from the U.S. Food and Drug Administration (the "FDA") for the AYON Body Contouring System ("AYON") to include power liposuction, an advanced form of liposuction that uses a reciprocating cannula to enhance efficiency of fat removal to reduce a surgeon's effort and operating room time. "With the addition of our advanced power liposuction function, we believe AYON is the gold-standard system in sur
- SECSEC Form 10-Q filed by Apyx Medical Corporation10-Q - Apyx Medical Corp (0000719135) (Filer)
- SECApyx Medical Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Apyx Medical Corp (0000719135) (Filer)
- PRApyx Medical Corporation Reports First Quarter 2026 Financial ResultsReported total revenue of $12.5 million in the first quarter of 2026 primarily driven by 36% growth in the Surgical Aesthetics segmentRaised total revenue guidance for FY2026 to a range of $59.0 million to $60.0 millionManagement to host a conference call today at 8:00 a.m. ET CLEARWATER, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today reported financial results for its first quarter ended March 31, 2026. Recent Financial and Operating Highlights: Reported total revenue of $12.5 million in the first quarter of
- PRApyx Medical Corporation to Release First Quarter of Fiscal Year 2026 Financial Results on May 7, 2026CLEARWATER, Fla., April 23, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the "Company" or "Apyx Medical"), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that its financial results for the first quarter of fiscal year 2026 will be released before markets open on Thursday, May 7th. Management will host a conference call at 8:00 a.m. Eastern Time on Thursday, May 7th, to discuss the results of the quarter, followed by a question-and-answer session. To listen to the call by phone, interested parties may dial 800-717-1738 (or 646-307-1865 for international callers) and provide access code 81537.
- PRRenuvion wins 2026 NewBeauty Award for "Best Minimally Invasive Skin Tightener"Renuvion continues to lead in minimally invasive body contouring as the trusted solution for loose skin. CLEARWATER, Fla., April 1, 2026 /PRNewswire/ -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical" or the "Company"), the leader in surgical aesthetics marketed and sold as Renuvion™ and the AYON Body Contouring System™ (AYON), today announced that Renuvion has been named this year's NewBeauty Award winner in the "Best Minimally Invasive Skin Tightener"1 category for the second consecutive year. "We're proud to be recognized by NewBeauty again," said Charlie Goodwin, Pres
- INSIDERSenior Vice President Citronowicz Moshe exercised 37,000 shares at a strike of $1.80, increasing direct ownership by 8% to 493,504 units (SEC Form 4)4 - Apyx Medical Corp (0000719135) (Issuer)
- ANALYSTApyx Medical upgraded by BTIG Research with a new price targetBTIG Research upgraded Apyx Medical from Neutral to Buy and set a new price target of $6.00
- SECSEC Form 10-K filed by Apyx Medical Corporation10-K - Apyx Medical Corp (0000719135) (Filer)
- SECApyx Medical Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Apyx Medical Corp (0000719135) (Filer)
- PRApyx Medical Corporation Reports Fourth Quarter and Full Year 2025 Financial ResultsReported record total revenue of $19.2 million in the fourth quarter of 2025Scaling U.S. commercial launch of AYON Body Contouring System™ (AYON) to meet strong market demandExpect FY2026 total revenue in the range of $57.5 million to $58.5 millionManagement to host a conference call today at 8:00 a.m. ET CLEARWATER, Fla., March 10, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today reported financial results for its fourth quarter and full year ended December 31, 2025. Recent Financial and Operating Highlights: Reported
- PRApyx Medical Corporation to Release Fourth Quarter of Fiscal Year 2025 Financial Results on March 10, 2026CLEARWATER, Fla., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the "Company" or "Apyx Medical"), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that its financial results for the fourth quarter of fiscal year 2025 will be released before markets open on Tuesday, March 10th. Management will host a conference call at 8:00 a.m. Eastern Time on Tuesday, March 10th, to discuss the results of the quarter, followed by a question-and-answer session. To listen to the call by phone, interested parties may dial 800-717-1738 (or 646-307-1865 for international callers) and provide access code 81
- PRApyx Medical Corporation to Participate in The Citizens Life Sciences ConferenceCLEARWATER, Fla., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the "Company" or "Apyx Medical"), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that management will participate in The Citizens Life Sciences Conference on Wednesday, March 11, 2026, in Miami, FL. Charlie Goodwin, the Company's President and Chief Executive Officer, and Matt Hill, the Company's Chief Financial Officer, will participate in a fireside chat on Wednesday, March 11, 2026, at 8:25am ET and will hold one-on-one meetings with investors throughout the day. The fireside chat will be accessible via live webcast h
- INSIDERChief Operating Officer Roman Shawn David exercised 12,000 shares at a strike of $1.80 (SEC Form 4)4 - Apyx Medical Corp (0000719135) (Issuer)
- PRApyx Medical Corporation to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools ConferenceCLEARWATER, Fla., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the "Company" or "Apyx Medical"), the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced that management will participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Tuesday, February 10, 2026 in Snowbird, Utah. To request a meeting with Apyx, investors should contact their BTIG representatives. About Apyx Medical Corporation: Apyx Medical Corporation is a surgical aesthetics company with a passion for elevating people's lives through innovative products, including its Helium
- SECApyx Medical Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Apyx Medical Corp (0000719135) (Filer)
- PRApyx Medical Corporation Reports Preliminary, Unaudited, Fourth Quarter and Full Year 2025 Revenue ResultsCLEARWATER, Fla., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the "Company" or "Apyx Medical") the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today reported preliminary revenue results for the fourth quarter and full year ended December 31, 2025. Preliminary Fourth Quarter 2025 Revenue Summary: Total revenue is expected to be in the range of approximately $19.0 to $19.2 million, representing an increase of approximately 34% year-over-year. Surgical Aesthetics revenue is expected to be in the range of approximately $16.6 to $16.8 million, representing an increase of approximately 38% year-over-yea
- SECSEC Form EFFECT filed by Apyx Medical CorporationEFFECT - Apyx Medical Corp (0000719135) (Filer)
APYX FAQ
6 questionsWhat does Apyx Medical Corporation do?
Apyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets worldwide. The company operates in two segments, Advanced Energy and OEM. It offers electrosurgical generators based on its Helium Plasma Technology for cutting, coagulation, and ablation of soft tissue. The company offers Renuvion branded products for the cosmetic surgery market that enable plastic surgeons, fascial plastic surgeons, and cosmetic physicians to provide controlled heat to the tissue to achieve their desired results; and J-Plasma branded...Where does APYX stock trade?
Apyx Medical Corporation (APYX) is listed on NASDAQ.What sector and industry is APYX in?
Apyx Medical Corporation operates in the Health Care sector, Medical/Dental Instruments industry.What are analysts saying about APYX?
Apyx Medical Corporation has had 8 recent analyst actions on file. The most recent action was from BTIG Research: Buy with a $600.00 price target on 2026-03-11. Recent price targets range from $600.00 to $1400.00.What companies are similar to APYX?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare APYX side-by-side with any of them on Quantisnow.How can I track APYX on Quantisnow?
Quantisnow aggregates Apyx Medical Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow APYX to receive live email and push alerts on every new disclosure.